RE:RE:RE:AstraZeneca's ADC disappoints - on severe adverse eventsDecember 21, 2023 - Sanofi pulls the plug on ADC after lung cancer PhIII disappoints.
The ADC, called tusamitamab ravtansine, originated from a long running deal with ImmunoGen. The trial in question was evaluating the drug as a monotherapy in previously treated patients with metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors express high levels of a cancer-driving protein called carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5).
[ ONCY has identified CEACAM6 as a biomarker in pancreatic cancer, for example]
Sanofi reinforces commitment to broader oncology development program including CEACAM5-directed antibody drug conjugates (ADC) with additional anticipated trials
https://www.sanofi.com/en/media-room/press-releases/2023/2023-12-21-06-30-00-2799759
https://www.fiercebiotech.com/biotech/sanofis-oncology-strategy-suffers-another-blow-adc-scrapped-over-phase-3-lung-cancer-fail
In November 2023 AbbVie agreed to pay $10.1 billion in cash to acquire ImmunoGen.
https://www.fiercepharma.com/pharma/abbvie-pays-10b-acquire-immunogen-doubling-down-red-hot-adc-cancer-field
https://www.sanofi.com/en/media-room/press-releases/2022/2022-03-16-10-18-19-2404147